The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
Launched by RUIJIN HOSPITAL · Dec 20, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new imaging method called 68Ga-FAPI PET/CT to see how effective it is in assessing treatment for patients with advanced liver cancer, specifically hepatocellular carcinoma (HCC), who cannot undergo surgery. The goal is to better understand how this imaging technique can help doctors evaluate how well patients are responding to their cancer treatments.
To participate in this study, you need to be between 18 and 75 years old and have a confirmed diagnosis of advanced unresectable HCC. You'll also need to provide consent to take part in the research and follow the study guidelines. However, if you have serious health issues like severe heart or lung problems, or if you're pregnant or breastfeeding, you won't be eligible to join. If you choose to participate, you'll undergo imaging tests and regular evaluations to track your treatment's effectiveness. This study is currently looking for participants, so it's a good opportunity for eligible patients to contribute to important cancer research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma patients.
- • 2. Signed and dated informed consent form.
- • 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process.
- • 4. Aged 18-75 years old.
- Exclusion Criteria:
- • 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- • 2. Intestinal perforation, complete intestinal obstruction
- • 3. Pregnant women and women who may be pregnant, women who are breastfeeding.
- • 4. Non-compliant person
About Ruijin Hospital
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading medical institution in China recognized for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, Ruijin Hospital integrates cutting-edge medical practices with rigorous scientific investigation. The hospital's multidisciplinary teams are dedicated to developing new therapeutic approaches, improving patient outcomes, and contributing to global medical knowledge. As a sponsor of clinical trials, Ruijin Hospital ensures adherence to the highest ethical standards and regulatory compliance, fostering an environment of collaboration and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported